🇺🇸 FDA
Patent

US 12281111

Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same

granted A61KA61K31/437A61K31/4545

Quick answer

US patent 12281111 (Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same) held by Aclaris Therapeutics, Inc. expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Aclaris Therapeutics, Inc.
Grant date
Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K31/437, A61K31/4545, A61K45/06, A61P